Highest-materiality recent filing
Q2 revenue $200.6M (-7.6% YoY); diluted EPS $0.01, adjusted diluted EPS $0.14.
Inspire Medical appoints Michael H. Carrel to Board of Directors
Michael H. Carrel, CEO of AtriCure (ATRC), appointed to Inspire Medical's Board as Class III director, effective July 20, 2026.
Inspire Medical board member Casey Tansey to retire effective July 30, 2026
Casey Tansey notified the Board of his retirement effective July 30, 2026, and will not stand for re-election at the 2027 Annual Meeting.
Inspire Medical to present at investor meetings in June 2026; materials available online
Company is participating in investor and analyst meetings in June 2026.
Inspire Medical shareholders approve declassification, 2.6M-share increase to equity plan
Stockholders approved phasing out classified board; all directors to be elected annually starting 2029.
Inspire Medical Q1 revenue up 1.6% to $204.6M; guides FY2026 revenue down 4-10%
GAAP diluted EPS $(0.39); adjusted diluted EPS $0.10; operating cash flow $12.8M.
Inspire Q4 rev $269M (+12%), EPS $4.66; FY26 outlook lowered on coding change
Q4 revenue $269.1M (+12%); GAAP diluted EPS $4.66; adjusted EPS $1.65.
Inspire Medical posts preliminary Q4 rev ~$269M (+12% YoY); 2026 guidance $1,003-1,013M
Preliminary Q4 2025 revenue ~$269M, up 12% YoY; full-year 2025 revenue ~$912M, up 14% YoY.
Inspire Medical Systems expects $90M-$100M tax benefit from valuation allowance release
Company disclosed expectation to release a significant portion of valuation allowance on U.S. deferred tax assets.
Revenue $224.5M in Q3 2025, up 10% from $203.2M a year ago; U.S. revenue $214.4M (+9%), OUS revenue $10.1M (+37%).
Singapore study (44 patients): Inspire V IPOP 87.1% vs Inspire IV 79.4%, exceeding non-inferiority margin of 4.6%.
Inspire Medical Systems CFO Rick Buchholz to step down by Dec 31, 2025; 2025 guidance reaffirmed
CFO Rick Buchholz resigns effective Dec 31, 2025, will remain in advisory role through Feb 28, 2026.
Inspire Medical Systems board authorizes $200M share repurchase program
Board authorized repurchase of up to $200M of common stock.
Inspire Medical Q2 net loss $3.6M, cuts FY 2025 revenue guidance to $900-910M
Q2 revenue $217.1M (+11% YoY), net loss $3.6M vs prior year net income $9.8M.
Inspire Medical Systems files investor presentation for June 2025 meetings
Company will participate in investor and analyst meetings in June 2025.
Inspire Medical Q1 rev $201.3M (+23% YoY), EPS $0.10; raises FY EPS guidance to $2.20-$2.30
Revenue $201.3M, up 23% YoY; U.S. revenue $193.6M (+24%), OUS $7.7M (-6%).
Inspire Medical stockholders approve all proposals at 2025 annual meeting
All three Class I director nominees elected: Burks (20.5M for), Herbert (21.1M for), McCormick (19.9M for).
Inspire Medical Q4 revenue $239.7M (+25% YoY); EPS $1.15; guides FY2025 rev $940-955M
Q4 revenue $239.7M (+25% YoY); net income $35.2M, diluted EPS $1.15 vs $0.49 prior year.
Inspire Medical reports Q4 revenue ~$239.7M (+25% YoY); issues 2025 guidance $940-955M
Preliminary Q4 2024 revenue ~$239.5-239.7M, up 25% YoY; full year 2024 revenue ~$802.6-802.8M, up 28% YoY.
Inspire Medical enters $75M accelerated share repurchase with Goldman Sachs
ASR agreement for $75M repurchase under existing $150M buyback program authorized by Board.
Inspire Medical Q3 revenue $203.2M (+33% YoY), EPS $0.60 vs loss, raises FY guidance
Revenue $203.2M, up 33% YoY; U.S. revenue $195.8M (+33%), OUS $7.4M (+27%).
Inspire Q2 revenue $195.9M (+30% YoY), EPS $0.32; raises FY guide, authorizes $150M buyback
Q2 revenue $195.9M (30% YoY), net income $9.8M vs loss $12.0M; diluted EPS $0.32 vs ($0.41).
Inspire Medical receives FDA approval for next-gen Inspire V neurostimulation system
FDA approved Inspire V system including next-generation neurostimulator, Bluetooth patient remote, and physician programmer.
Inspire Medical pre-announces Q2 revenue $195.9M (+30% YoY), raises 2024 guidance to $788-798M
Q2 revenue $195.9M, up 30% YoY; US revenue $187.8M (+30%), OUS $8.1M (+27%).
Philip J. Ebeling notified Inspire Medical on July 18, 2024 of his resignation as COO, effective Aug 9, 2024.
Inspire Medical Q1 revenue $164M (+28% YoY); raises FY2024 guidance, expects full-year profitability
Q1 2024 revenue $164.0M, up 28% YoY; net loss narrowed to $10.0M ($0.34/share) from $15.4M.
Inspire Medical shareholders elect directors, ratify auditor, approve say-on-pay
All three Class III director nominees elected: Broader (26.3M for), Dr. Curet (23.5M for), Tansey (26.1M for).
Inspire Medical Q4 revenue $192.5M (+40%), first net income quarter $14.8M
Q4 revenue $192.5M (+40% YoY); full year $624.8M (+53%). U.S. revenue $189.4M (+41%).
Inspire Medical CEO Tim Herbert to succeed Marilyn Carlson Nelson as Board Chair
Marilyn Carlson Nelson will retire as Board Chair at the May 2, 2024 annual meeting; departure not due to any disagreement.
Inspire Medical board member Jerry C. Griffin retiring after 16 years
Dr. Griffin will retire effective at the conclusion of the 2024 Annual Meeting on May 2, 2024.
Inspire Medical Systems Q4 preliminary revenue ~$192.4M (+40% YoY); FY2024 guidance $775-785M
Q4 2023 revenue expected $192.3-192.5M, ~40% increase over Q4 2022.
Inspire Medical appoints Intuitive Surgical executive Myriam Curet to board
Appointed Myriam J. Curet, M.D. as independent director, effective Dec 21, 2023.
Inspire Medical Q3 revenue $153.3M (+40% YoY); raises FY2023 guidance to $608-612M
Net loss narrowed to $8.5M ($0.29 per share) from $16.8M ($0.60) YoY.
Company will attend multiple investor meetings in November and December 2023.
Inspire Med: Q2 rev $151.1M (+65% YoY), raises FY2023 guidance to $600-610M
Revenue of $151.1M, up 65% YoY; U.S. rev $144.7M (+65%), OUS $6.3M (+81%).
Inspire Medical furnishes generic investor presentation; no new financial data
Company participating in investor and analyst meetings in August and September 2023.
Over 41,000 Inspire procedures completed to date; ADHERE registry has 4,800 enrollments at 62 centers.
Inspire Medical Q1 revenue up 84% to $127.9M; raises FY 2023 guidance to $580-590M
Revenue $127.9M (+84% YoY); U.S. revenue $124.5M (+87% YoY); gross margin 84.4%.
Inspire Medical Systems provides updated investor presentation for Q2 2023 meetings
Company to participate in multiple investor meetings during May and June 2023.
Inspire Medical Systems stockholders elect directors, ratify auditor, approve exec compensation
All four Class II director nominees elected; Gary L. Ellis received 9.6M withheld (37.6% of votes cast).
Q4 2022 net income $3.2M, diluted EPS $0.10, vs. loss of $2.4M in Q4 2021.
Inspire Medical Systems releases Feb 2023 investor presentation; no material news disclosed
Company participating in investor meetings in February and March 2023.
Inspire Medical Q4 preliminary revenue ~$137.7M (+76% YoY); FY22 ~$407.7M (+75%)
Q4 2022 preliminary revenue $137.5M-$137.9M, ~76% YoY increase.
Inspire Medical presents at JP Morgan Healthcare Conference; no financial results disclosed
Company participating in investor meetings on January 9, 2023; presentation posted on IR website.
Inspire Medical Q3 revenue $109.2M (+77% YoY); raises FY2022 guidance to $384-388M
Revenue $109.2M (+77% YoY); raised FY2022 guidance to $384-388M from $354-362M.
Inspire Medical prepays all loans under Oxford Finance agreement, terminates Loan Agreement
Prepaid in full all outstanding loans under Loan & Security Agreement with Oxford Finance LLC on August 19, 2022.
Inspire Medical Systems prices public offering of 1M shares at $215/share; net proceeds ~$243.8M
Offering of 1,000,000 shares at $215.00 per share; underwriter option for 150,000 shares exercised in full.
Inspire Medical expands board to 11, appoints Burks and Sparks as directors
Board expanded to 11 directors; Cynthia Burks and Dr. Charisse Sparks appointed effective July 28, 2022.
Inspire Medical Q2 revenue $91.4M (+73%), net loss $14.5M; FY guidance raised to $354M-$362M
Q2 revenue $91.4M (+73% YoY); U.S. $87.9M (+78%), ex-U.S. $3.5M (-3% due to FX).
Inspire Medical amends loan agreement to set German subsidiary asset and income limits
German subsidiary GMBH exempted from subsidiary joinder requirements in loan agreement.
On July 20, 2026, the Board of Directors (the “Board”) of Inspire Medical Systems, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Michael H. Carrel to the Board, effective immediately.
On July 18, 2024, Philip J. Ebeling notified Inspire Medical Systems, Inc. (the “ Company ”) of his decision to resign as Chief Operating Officer of the Company, effective as of August 9, 2024, in order to pursue a new professional opportunity as President and Chief Executive Officer of a private medical device company operating in the cardiology space.
Marilyn Carlson Nelson, Chair of the Board of Directors (the “Board”) of Inspire Medical Systems, Inc. (the “Company”), notified the Company of her decision to retire from the Board and not stand for re-election at the Company’s 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”) scheduled to occur on May 2, 2024.
the Board has appointed Chief Executive Officer Timothy P. Herbert to the additional role of Board Chair, succeeding Ms. Nelson, to be effective at the conclusion of the 2024 Annual Meeting.
The Board has appointed Gary Ellis to the role of Lead Independent Director to be effective at the conclusion of the 2024 Annual Meeting.
On January 22, 2024, Jerry C. Griffin, M.D., a member of the Board of Directors (the “Board”) of Inspire Medical Systems, Inc. (the “Company”), notified the Company of his decision to retire from the Board and not stand for re-election at the Company’s 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”).
On December 21, 2023, the Board of Directors (the “Board”) of Inspire Medical Systems, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Myriam J. Curet, M.D., to the Board, effective immediately.
On July 31, 2023, the Company announced that Charisse Y. Sparks, M.D., was appointed to serve as its Chief Medical Officer, effective July 27, 2023.
In connection with her appointment as Chief Medical Officer of the Company, on July 27, 2023, Dr. Sparks resigned from the Board of Directors, including the Nominating and Corporate Governance Committee, effective upon the commencement of service as Chief Medical Officer.
expanded the size of the Board to eleven directors, and appointed Cynthia Burks and Charisse Y. Sparks, M.D. to the Board, effective immediately.
expanded the size of the Board to eleven directors, and appointed Cynthia Burks and Charisse Y. Sparks, M.D. to the Board, effective immediately.
Max materiality 0.85 · Median 0.68 · Most common event earnings